Vasotec I.V. Related Published Studies
Well-designed clinical trials related to Vasotec I.V. (Enalaprilat)
Myocardial protection with enalaprilat in patients unresponsive to ischemic preconditioning during percutaneous coronary intervention. [2008.12]
Pretreatment with intracoronary enalaprilat protects human myocardium during percutaneous coronary angioplasty. [2007.04.17]
Effects of enalaprilat infusion on hemodynamics and renal function in patients undergoing cardiac surgery. [2004.12]
Effects of enalaprilat on venoconstriction to norepinephrine: role of prostaglandins. [2003.07.01]
Effect of enalaprilat on postoperative hypertension after surgical repair of coarctation of the aorta. [2003.07]
Beneficial hemodynamic and renal effects of intravenous enalaprilat following coronary artery bypass surgery complicated by left ventricular dysfunction. [2003.05]
Effects of intracoronary low-dose enalaprilat as an adjunct to primary percutaneous transluminal coronary angiography in acute myocardial infarction. [2001.12.15]
Effects of enalaprilat on cardiorespiratory, hemodynamic, and hematologic variables in exercising horses. [2001.07]
Haemodynamic and renal effects of intravenous enalaprilat during coronary artery bypass graft surgery in patients with ischaemic heart dysfunction. [2001.02]
Quinaprilat-induced vasodilatation in forearm vasculature of patients with essential hypertension: comparison with enalaprilat. [2000.12]
Comparison of the pharmacokinetics of fosinoprilat with enalaprilat and lisinopril in patients with congestive heart failure and chronic renal insufficiency. [2000.01]
[Sublingual nitroglycerin or intravenous enalaprilat in preclinical treatment of hypertensive patients with pulmonary edema] [1999.03]
Bolus versus continuous low dose of enalaprilat in congestive heart failure with acute refractory decompensation. [1999]
Differential effects of quinaprilat and enalaprilat on endothelial function of conduit arteries in patients with chronic heart failure. [1998.12.22]
Influence of angiotensin-converting enzyme inhibitor enalaprilat on endothelial-derived substances in the critically ill. [1998.10]
The effect of i.v. enalaprilat in chronically treated hypertensive patients during cardiac surgery. [1998.09]
Attenuation of thrombolysis-induced increase of plasminogen activator inhibitor-1 by intravenous enalaprilat. [1998.01]
Placebo-controlled, randomized, double-blind study of intravenous enalaprilat efficacy and safety in acute cardiogenic pulmonary edema. [1996.09.15]
Can clonidine, enoximone, and enalaprilat help to protect the myocardium against ischaemia in cardiac surgery? [1996.09]
Acute administration of metoprolol and enalaprilat reduces insulin-stimulated thermogenesis and skin blood flow. [1996.05]
Clinical evaluation of different doses of intravenous enalaprilat in patients with hypertensive crises. [1995.11.13]
Cardiorespiratory effects of continuous i.v. administration of the ACE inhibitor enalaprilat in the critically ill. [1995.11]
Enalaprilat controls postoperative hypertension while maintaining cardiac function and systemic oxygenation after neurosurgery. [1995.08]
Intraoperative hemodynamic, renin, and catecholamine responses after prophylactic and intraoperative administration of intravenous enalaprilat. [1995.03]
Influence of intravenous administration of angiotensin-converting enzyme inhibitor enalaprilat on cardiovascular mediators in cardiac surgery patients. [1995.03]
Continuous i.v. administration of the angiotensin-converting enzyme inhibitor enalaprilat in the critically ill: effects on regulators of circulatory homeostasis. [1995.03]
Cardiorespiratory response of intravenous angiotensin-converting enzyme inhibitor enalaprilat in hypertensive cardiac surgery patients. [1995.02]
Isolated circulatory response to intravenous administration of the ACE inhibitor enalaprilat. [1994.04]
Effects of enalaprilat on hemodynamics and ventricular activation duration in hypertensive patients with left ventricular hypertrophy: clinical evidence of improved excitation-contraction coupling with angiotensin converting enzyme inhibition in human hypertension. [1993.07]
Lack of effect of enalaprilat on the action of vasoactive intestinal polypeptide in the human forearm. [1993.05]
Double blind controlled study of low dose intravenous perindoprilat or enalaprilat infusion in elderly patients with heart failure. [1993.04]
The effect of saturation of ACE binding sites on the pharmacokinetics of enalaprilat in man. [1992.02]
Effect of intravenous enalaprilat in moderate and severe systemic hypertension. [1988.11.15]
Well-designed clinical trials possibly related to Vasotec I.V. (Enalaprilat)
Enalapril dosage in progressive chronic nephropathy: a randomised, controlled trial. [2005.04]
Evaluation of the bioequivalence of two tablet formulations of enalapril/hydrochlorothiazide after single oral administration to healthy volunteers. [2004]
Relative bioavailability study of 20-mg enalapril tablets in healthy male volunteers. [2003.10]
Bioequivalence evaluation of two brands of enalapril 20 mg tablets (Narapril and Renitec) in healthy human volunteers. [2003.10]
Bioequivalence study of two brands of enalapril tablets after single oral administration to healthy volunteers. [2003.05]
Enalapril does not alter adhesion molecule levels in human endotoxemia. [2003.05]
Angiotensin-converting enzyme inhibition increases human vascular tissue-type plasminogen activator release through endogenous bradykinin. [2003.02.04]
Blood pressure response to conventional and low-dose enalapril in chronic renal failure. [2003.02]
Bioequivalence study of enalapril tablets in healthy Thai male volunteers. [2002.06]
Comparative bioavailability of two immediate release tablets of enalapril/hydrochlorothiazide in healthy volunteers. [2002.04]
Sevelamer hydrochloride (Renagel), a phosphate-binding polymer, does not alter the pharmacokinetics of two commonly used antihypertensives in healthy volunteers. [2001.02]
Pharmacokinetic assessment of an oral enalapril suspension for use in children. [2000.12]
A comparative study between a calcium channel blocker (Nicardipine) and a combined alpha-beta-blocker (Labetalol) for the control of emergence hypertension during craniotomy for tumor surgery. [2000.10]
Enalapril in RAPIDISC (wafer formulation): pharmacokinetic evaluation of a novel, convenient formulation. [2000.07]
The use of metoprolol and glycopyrrolate to prevent hypotensive/bradycardic events during shoulder arthroscopy in the sitting position under interscalene block. [1998.12]
Effects of acute ACE inhibition on pulsatile renin and aldosterone secretion and their synchrony. [1998.11]
Cough-challenge trial with a new angiotensin-converting enzyme inhibitor, imidapril. [1998.05]
[The changes of PRA, ATII, ald, ET and ANP in patients with left ventricular diastolic heart failure and intervention with enalapril] [1997]
Mechanism of angiotensin converting enzyme inhibitor-related anemia in renal transplant recipients. [1996.09]
Benefit of converting enzyme inhibition on left ventricular volumes and ejection fraction in patients receiving beta-blockade after myocardial infarction. CONSENSUS II multiecho study group. [1996.07]
Blood pressure reduction initiates the antiproteinuric effect of ACE inhibition. [1996.01]
Effect of hydrochlorothiazide on the pharmacokinetics of enalapril in hypertensive patients with varying renal function. [1996.01]
Effect of early enalapril therapy on left ventricular function and structure in acute myocardial infarction. [1995.10.15]
Chronopharmacology of enalapril in hypertensive patients. [1995]
Neurohormonal activation in patients with acute myocardial infarction or chronic congestive heart failure. With special reference to treatment with angiotensin converting enzyme inhibitors. [1995]
Angiotensinergic versus nonangiotensinergic hemodynamic effects of converting enzyme inhibition in patients with chronic heart failure. Assessment by acute renin and converting enzyme inhibition. [1994.12]
Endogenous vasopressin and renin-angiotensin systems support blood pressure after epidural block in humans. [1994.05]
Attenuation of left ventricular dilatation after acute myocardial infarction by early initiation of enalapril therapy. CONSENSUS II Multi-Echo Study Group. [1993.11.01]
Effect on exercise performance of enalapril therapy initiated early after myocardial infarction. Nordic Enalapril exercise Trial. [1993.10]
The effects of age on the pharmacokinetics and pharmacodynamics of single oral doses of benazepril and enalapril. [1993.09]
Angiotensin-converting enzyme inhibitors in heart failure: blood pressure changes after the first dose. [1993.09]
Cardiovascular effects, pharmacokinetics, and converting enzyme inhibition of enalapril after morning versus evening administration. [1993.08]
Blood pressure response to the first dose of angiotensin-converting enzyme inhibitors in congestive heart failure. [1993.06.24]
Reversal of cardiovascular structural changes when treating essential hypertension. The importance of the renin-angiotensin-aldosterone system. [1992.12]
Reduction in cardiac conduction velocity delay by angiotensin converting enzyme inhibition in hypertensive patients with left ventricular hypertrophy. Detection by signal averaged electrocardiography. [1992.12]
Effect of enalapril treatment and sclerotherapy of esophageal varices on hepatic hemodynamics in portal hypertension. [1992.12]
Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II) [1992.09.03]
The influence of hydrochlorothiazide on the pharmacokinetics of enalapril in elderly patients. [1992]
Converting enzyme inhibitors and the role of the sulfhydryl group in the potentiation of exo- and endogenous nitrovasodilators. [1991.09]
Pharmacokinetic comparison of a combination tablet of enalapril and hydrochlorothiazide with enalapril and hydrochlorothiazide tablets administered together and separately. [1991.08]
Determinants of angiotensin II generation during converting enzyme inhibition. [1990.11]
Effect of acute angiotensin converting enzyme inhibition on left ventricular filling in patients with congestive heart failure. Relation to right ventricular volumes. [1990.02]
Pharmacokinetics of lisinopril (IV/PO) in healthy volunteers. [1989.07]
The effect of local angiotensin converting enzyme inhibition on the action of atrial natriuretic peptide in the human forearm. [1989.02]
Comparison of increase in the enalapril dose and addition of hydrochlorothiazide as second-step treatment of hypertensive patients not controlled by enalapril alone. [1989.02]
Individual responses to converting enzyme inhibitors and calcium antagonists. [1988.02]
A randomized cross-over study of enalapril in congestive heart failure: haemodynamic and hormonal effects during rest and exercise. [1988]
Effect of cimetidine on the pharmacokinetics and pharmacodynamics of enalapril in normal volunteers. [1988]
An evaluation of the pharmacodynamics and pharmacokinetics of nicardipine combined with enalapril in essential hypertension. [1987.12]
Acute antihypertensive effect of angiotensin converting enzyme inhibition and calcium entry blockade. [1987]
Other research related to Vasotec I.V. (Enalaprilat)
Acute effects of the ACE inhibitor enalaprilat on the pulmonary, cerebral and systemic blood flow and resistance after the bidirectional cavopulmonary connection. [2011.08]
Sublingual microcirculatory effects of enalaprilat in an ovine model of septic shock. [2011.06]
Enalaprilat and enalapril maleate eyedrops lower intraocular pressure in rabbits. [2010.05]
[Effects of single or combined administration of cedilanid and enalaprilat on visceral damages in early stage of severe scald in rats] [2008.12]
[Protective effect of enalaprilat injection against early postburn organ damage in rats] [2008.07.01]
[Protective effects of enalaprilat on the myocardial kinetics in rats at early stage of severe scald] [2008.06]
Enalaprilat induced acute parotitis. [2008.02]
Effects of enalaprilat on acute necrotizing pancreatitis in rats. [2007.12]
Effects of intracoronary low-dose enalaprilat on ventricular repolarization dynamics after direct percutaneous intervention for acute myocardial infarction. [2007.05]
Intracoronary enalaprilat during angioplasty for acute myocardial infarction: alleviation of postischaemic neurohumoral and inflammatory stress? [2007.02]
Low doses of intracoronary enalaprilat suppress reperfusion-associated ventricular arrhythmias after primary percutaneous coronary interventions for acute myocardial infarction. [2007.01]
Systemic and regional hemodynamic effects of enalaprilat infusion in experimental normotensive sepsis. [2006.09]
The effect of sublingual captopril versus intravenous enalaprilat on angiotensin II plasma levels. [2006.06]
Effects of enalaprilat on the renin-angiotensin-aldosterone system and on renal function during CO2 pneumoperitoneum. [2005.10]
Pharmacokinetics and pharmacodynamics profiles of enalapril maleate in healthy volunteers following determination of enalapril and enalaprilat by two specific enzyme immunoassays. [2005.08]
Gender differences in angiotensin-converting enzyme (ACE) activity and inhibition by enalaprilat in healthy volunteers. [2004.05]
Losartan but not enalaprilat acutely reduces reperfusion ventricular tachyarrhythmias in hypertrophied rat hearts after low-flow ischaemia. [2004.04]
Evaluation of the efficacy, safety and tolerability of intravenous enalaprilat in the treatment of grade III essential hypertension in Indian patients. [2004.01]
|
